GlassScriptPhysician profile
Michael A Alexander
NPI 1366779837
$2,433.44
in general payments reported to CMS, 2019-2025
17 companies · $1,016 in 2025
The $1,016 reported for 2025 was more than what 86% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $30.81 · 2020: $15.31 · 2021: $111 · 2022: $82.51 · 2023: $374 · 2024: $804 · 2025: $1,016.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,179 · Education: $14.85.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,178.58 |
| Education | $14.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Braeburn INC. | $444.22 | 2023-2025 | Brixadi |
| Alkermes, INC. | $443.83 | 2019-2025 | Lybalvi, Aristada, Vivitrol |
| Lilly USA, LLC | $415.26 | 2023-2025 | Zepbound, Mounjaro, Jardiance |
| Indivior INC. | $373.18 | 2019-2025 | Sublocade |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $139.10 | 2023-2024 | Caplyta |
| Axsome Therapeutics, INC. | $130.26 | 2024-2025 | Auvelity |
| Exact Sciences Corporation | $95.56 | 2024-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Orexo US, INC. | $88.52 | 2024-2025 | Zubsolv |
| Abbvie INC. | $84.08 | 2022-2025 | Vraylar |
| Corium, LLC | $52.65 | 2025 | Azstarys |
| Janssen Pharmaceuticals, INC | $39.34 | 2023 | Spravato |
| Novo Nordisk INC | $33.26 | 2025 | Wegovy |
| Otsuka America Pharmaceutical, INC. | $25.39 | 2021 | |
| Almatica Pharma LLC | $22.37 | 2023 | Loreev Xr |
| Acelrx Pharmaceuticals, INC. | $20.78 | 2021 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Currax Pharmaceuticals LLC | $14.46 | 2023 | Onzetra Xsail, Contrave |
| Pear Therapeutics (US), INC. | $11.18 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Alexander listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.